Share this Article
You are free to share this article under the Attribution 4.0 International license.
The CRISPR gene editing technique may provide the means for lifelong correction of the genetic mutation responsible for Duchenne muscular dystrophy, a new study with mice shows.
Duchenne muscular dystrophy (DMD), a rare but devastating genetic disorder, causes muscle loss and physical impairment. Children with DMD have a gene mutation that interrupts the production of a protein known as dystrophin. Without it, muscle cells weaken and eventually die. Many children lose the ability to walk, and muscles essential for breathing and heart function ultimately stop working.
Research has shown that CRISPR can be used to edit out the mutation that causes the early death of muscle cells in an animal model, says Dongsheng Duan, professor in medical research in the molecular microbiology and immunology department at the University of Missouri School of Medicine and senior author of the paper in Molecular Therapy.
However, there is a major concern of relapse because these gene-edited muscle cells wear out over time. If we can correct the mutation in muscle stem cells, then cells regenerated from the edited stem cells will no longer carry the mutation. A one-time treatment of the muscle stem cells with CRISPR could result in continuous dystrophin expression in regenerated muscle cells.
For the study, researchers explored whether they could efficiently edit muscle stem cells from mice. They first delivered the gene editing tools to normal mouse muscle through AAV9, a virus that the US Food and Drug Administration recently approved to treat spinal muscular atrophy.
We transplanted AAV9 treated muscle into an immune-deficient mouse, says lead author Michael Nance, a MD-PhD program student in Duans lab. The transplanted muscle died first then regenerated from its stem cells. If the stem cells were successfully edited, the regenerated muscle cells should also carry the edited gene.
The researchers reasoning was correctthey found abundant edited cells in the regenerated muscle. They then tested if they could use CRISPR to edit muscle stem cells in a mouse model of DMD. Similar to what they found in normal muscle, the stem cells in the diseased muscle were also edited. Cells regenerated from these edited cells successfully produced dystrophin.
This finding suggests that CRISPR gene editing may provide a method for lifelong correction of the genetic mutation in DMD and potentially other muscle diseases, Duan says.
Our research shows that CRISPR can be used to effectively edit the stem cells responsible for muscle regeneration. The ability to treat the stem cells that are responsible for maintaining muscle growth may pave the way for a one-time treatment that can provide a source of gene-edited cells throughout a patients life.
With more study, the researchers hope this stem cell-targeted CRISPR approach may one day lead to long-lasting therapies for children with DMD.
Additional coauthors are from the University of Missouri, the National Center for Advancing Translational Sciences, Johns Hopkins School of Medicine, and Duke University. The National Institutes of Health, the Department of Defense, the Jackson Freel DMD Research Fund, Hope for Javier, and the Intramural Research Program of the National Center for Advancing Translational Sciences funded the work.
Source: University of Missouri
The rest is here:
- New method provides unique insight into the development of the human brain - Science Codex - May 27th, 2020
- Importance of Biopsy and Tissue Analysis in Oncology - Patch.com - May 27th, 2020
- Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19... - May 27th, 2020
- Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COO - Business Wire - May 27th, 2020
- Couple on the coronavirus front lines - UCI News - May 27th, 2020
- Why Portugal's Covid-19 test rate is more than double almost every other nation - Telegraph.co.uk - May 27th, 2020
- Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 b | DDDT - Dove Medical Press - May 27th, 2020
- Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple... - May 27th, 2020
- Nine Harvard faculty elected to National Academy of Sciences - Harvard Gazette - May 15th, 2020
- Researcher Qing Wang Arrested, Allegedly Failed To Disclose China Ties - NPR - May 15th, 2020
- Why ETF Investors Should Consider Allocating to Innovation - ETF Trends - May 15th, 2020
- The Dialogue with Kanchan: Centre of Molecular Medicine at JNU has started working on a COVID 19 vaccine by tweaking the BCG vaccine - Free Press... - May 15th, 2020
- Lexent Bio Announces Use of its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer Therapeutics -... - May 15th, 2020
- Smothering the Fire - Harvard Medical School - May 15th, 2020
- Dornsife Scholars exemplify academic distinction with an international perspective > News > USC Dornsife - USC Dornsife College of Letters, Arts... - May 15th, 2020
- Cellworks Singula Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments -... - May 15th, 2020
- Research on Nuclear Medicine Molecular Imaging Technology Market (impact of COVID-19) with Top Players: Toshiba, GE Healthcare, Segami Corporation,... - May 15th, 2020
- Global Molecular Microbiology Market Trends, Applications, Competitive Strategies and Future Outlook 2025 - Cole of Duty - May 15th, 2020
- CareDx, Veracyte Enter Exclusive Partnership for Transplant Rejection Testing - Clinical OMICs News - May 15th, 2020
- Coronavirus found in semen of young men with COVID-19 - Bay 93.9 - May 15th, 2020
- Board of Governors honors professors for scholarly achievements - The South End - May 9th, 2020
- Foundation Medicine Receives FDA Approval for FoundationOneCDx as the Companion Diagnostic for Tabrecta (capmatinib), the Only FDA-Approved MET... - May 9th, 2020
- Patton named CEO of OneOncology - The Cancer Letter - May 9th, 2020
- Ventus Launches with $60 Million to Study Diseases of the Innate Immune System - BioSpace - May 9th, 2020
- Two New Research Institutes in the Bay Area - WFMZ Allentown - May 9th, 2020
- Thomas Lynch obituary: Pharma executive with passion for public health - The Irish Times - May 9th, 2020
- Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health - May 1st, 2020
- Five HMS Faculty Elected to National Academy of Sciences - Harvard Medical School - May 1st, 2020
- Four UTSW Researchers Named to The National Academy of Sciences - D Magazine - May 1st, 2020
- Old Drugs May Find a New Purpose: Fighting the Coronavirus - The New York Times - May 1st, 2020
- Taking the fight to superbugs - Times Higher Education (THE) - May 1st, 2020
- CU Anschutz Researchers Win Grant to Study Covid-19 Effects on Heart - CU Anschutz Today - May 1st, 2020
- Premier League stars with coronavirus symptoms to have lung and heart tests before return - Mirror Online - May 1st, 2020
- Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social... - May 1st, 2020
- Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies - Yahoo Finance - May 1st, 2020
- Outsmarting cancer: Innovative treatments and diagnostics offer new hope - Stanford Medical Center Report - May 1st, 2020
- We can't reopen the country without answering these 3 questions - The Daily Briefing - April 19th, 2020
- Can COVID-19 infect you twice? Mystery cases show how little is known about the virus - National Post - April 19th, 2020
- Scientists find doing this simple activity every day can help fend off dying of COVID-19 - Ladders - April 19th, 2020
- COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market - Xconomy - April 19th, 2020
- Veterinary medicine at the forefront in the fight against COVID-19 - dvm360 - April 19th, 2020
- 'Open the doors for us.' Indonesian scientists say government snubs offers to help fight coronavirus - Science Magazine - April 19th, 2020
- The Painkiller We Really Need Might Come From Spider Venom - IFLScience - April 19th, 2020
- Coronavirus and the Heart - Harvard Medical School - April 19th, 2020
- Sudbury Accent: The best and worse case scenarios for COVID-19 - The Sudbury Star - April 19th, 2020
- Research in most university labs moved from bench to internet - Washington University in St. Louis Newsroom - April 19th, 2020
- 'Smart toilet' recognizes users and checks for signs of disease - Medical News Today - April 19th, 2020
- 'I focus on low-cost tech to fight infectious diseases' - Business Mirror - April 19th, 2020
- Coronavirus in Ireland: What we know so far - The Irish Times - April 19th, 2020
- Hitting the Reset Button on Antibiotics - CTech - April 19th, 2020
- Antibodies in blood of COVID-19 survivors can beat coronavirus and researchers are already using them for new treatments - Raw Story - April 2nd, 2020
- How researchers are trying to harness the blood of coronavirus survivors to beat infection - AlterNet - April 2nd, 2020
- Mexico is already testing its own Covid-19 vaccine - The Yucatan Times - April 2nd, 2020
- Why are young, healthy people dying from COVID-19? Genes may reveal the answer. - Live Science - April 2nd, 2020
- How sick will the coronavirus make you? The answer may be in your genes - Science Magazine - April 2nd, 2020
- The Rise of Micro and Nanoflow In Proteomics - Technology Networks - April 2nd, 2020
- The Shared Misery of Zoom: Making Memes in a Time of Crisis - The Dartmouth - April 2nd, 2020
- Why is coronavirus killing more men than women? - Wired.co.uk - April 2nd, 2020
- Smoking and coronavirus: How dangerous is smoking amid coronavirus outbreak? - Express - April 2nd, 2020
- FDA Says Hydroxychloroquine and Chloroquine Can Be Used to Treat Coronavirus - Newsweek - April 2nd, 2020
- Vaccines: what are they and how do they work? - Daily Maverick - April 2nd, 2020
- A (now isolated) scientist who isolated the COVID-19 virus explains the fight for a vaccine - Toronto Star - April 2nd, 2020
- Pandemic science - The News International - April 2nd, 2020
- Applying Artificial Intelligence in the Fight Against The Coronavirus - HIT Consultant - April 2nd, 2020
- COVID-19 breakthrough: researchers from U of T and McMaster successfully isolate virus - Varsity - April 2nd, 2020
- This is how my team isolated the new coronavirus to fight the global pandemic - ThePrint - April 2nd, 2020
- Molecular Medicine | Home - March 31st, 2020
- Molecular Medicine (MolMed) | Duke School of Medicine - March 31st, 2020
- Master of Science (MSc) in Molecular Medicine - Trondheim ... - March 31st, 2020
- Section of Molecular Medicine | Wake Forest School of Medicine - March 31st, 2020
- Unlocking the Secrets of Brown Fat - Michigan Medicine - March 31st, 2020
- What Does Our Body Temperature Say About Our Health? - The New York Times - March 31st, 2020
- We are running out of money, don't have jobs: Several Indians stuck in Ireland seek to return home - Mumbai Mirror - March 31st, 2020
- Possible COVID-19 treatment: transfusion of antibodies from recovered patients' blood - Washington University School of Medicine in St. Louis - March 26th, 2020
- Tulane medical students coordinate donations of protective gear for hospitals - News from Tulane - March 26th, 2020
- New study: Molecular Cytogenetics Market size, share, industry analysis, growth and forecast 2025 - WhaTech Technology and Markets News - March 26th, 2020
- Could existing drugs help combat Covid-19? NZ experts weigh in - The Spinoff - March 26th, 2020
- More private labs approved for coronavirus testing: Here is full list - DNA India - March 26th, 2020
- CHAMPIGNON BRANDS APPOINTS DR. JOSEPH GABRIELE, ERNST & YOUNG 2018 HEALTH CARE ENTREPRENEUR OF THE YEAR AND DELIVRA INVENTOR TO SPECIAL ADVISORY... - March 26th, 2020
- Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC-Amifostine as a potentially effective theranostic technology for... - March 26th, 2020